[ Special series on Nasopharyngeal carcinoma ]
doi: 10.1186/s40880-015-0011-0
Multiple oncogenic mutations related to targeted therapy in nasopharyngeal carcinoma
Jian-Wei Zhang, Tao Qin, Shao-Dong Hong, Jing Zhang, Wen-Feng Fang, Yuan-Yuan Zhao, Yun-Peng Yang, Cong Xue, Yan Huang, Hong-Yuan Zhao, Yu-Xiang Ma, Zhi-Huang Hu, Pei-Yu Huang and Li Zhang
Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, Guangdong, P. R. China
[Abstract]
Introduction
An increasing number of targeted drugs have been tested for the treatment of nasopharyngeal carcinoma (NPC). However, targeted therapy-related oncogenic mutations have not been fully evaluated. This study aimed to detect targeted therapy-related oncogenic mutations in NPC and to determine which targeted therapy might be potentially effective in treating NPC.
Method
By using the SNaPshot assay, a rapid detection method, 19 mutation hotspots in 6 targeted therapy-related oncogenes were examined in 70 NPC patients. The associations between oncogenic mutations and clinicopathologic factors were analyzed.
Results
Among 70 patients, 12 (17.1%) had mutations in 5 oncogenes: 7 (10.0%) had v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog (KIT) mutation, 2 (2.8%) had epidermal growth factor receptor (EGFR) mutation, 1 (1.4%) had phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha (PIK3CA) mutation, 1 (1.4%) had Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation, and 1 (1.4%) had simultaneous EGFR and v-Raf murine sarcoma viral oncogene homolog B1 (BRAF) mutations. No significant differences were observed between oncogenic mutations and clinicopathologic characteristics. Additionally, these oncogenic mutations were not associated with tumor recurrence or metastasis.
Conclusions
Oncogenic mutations are present in NPC patients. The efficacy of targeted drugs on patients with the related oncogenic mutations requires further validation.
Introduction
An increasing number of targeted drugs have been tested for the treatment of nasopharyngeal carcinoma (NPC). However, targeted therapy-related oncogenic mutations have not been fully evaluated. This study aimed to detect targeted therapy-related oncogenic mutations in NPC and to determine which targeted therapy might be potentially effective in treating NPC.
Method
By using the SNaPshot assay, a rapid detection method, 19 mutation hotspots in 6 targeted therapy-related oncogenes were examined in 70 NPC patients. The associations between oncogenic mutations and clinicopathologic factors were analyzed.
Results
Among 70 patients, 12 (17.1%) had mutations in 5 oncogenes: 7 (10.0%) had v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog (KIT) mutation, 2 (2.8%) had epidermal growth factor receptor (EGFR) mutation, 1 (1.4%) had phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha (PIK3CA) mutation, 1 (1.4%) had Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation, and 1 (1.4%) had simultaneous EGFR and v-Raf murine sarcoma viral oncogene homolog B1 (BRAF) mutations. No significant differences were observed between oncogenic mutations and clinicopathologic characteristics. Additionally, these oncogenic mutations were not associated with tumor recurrence or metastasis.
Conclusions
Oncogenic mutations are present in NPC patients. The efficacy of targeted drugs on patients with the related oncogenic mutations requires further validation.
Chinese Journal of Cancer 2015, Volume: 34, Issue 4
[ PDF Full-text ]
[ Html full-text / Citation export] (BioMed Central)
[Google Scholar]
[ More articles of the special series on Nasopharyngeal carcinoma ]
Cite this article
Jian-Wei Zhang, Tao Qin, Shao-Dong Hong, Jing Zhang, Wen-Feng Fang, Yuan-Yuan Zhao, Yun-Peng Yang, Cong Xue, Yan Huang, Hong-Yuan Zhao, Yu-Xiang Ma, Zhi-Huang Hu, Pei-Yu Huang and Li Zhang. Multiple oncogenic mutations related to targeted therapy in nasopharyngeal carcinoma. Chin J Cancer. 2015, 34:10. doi:10.1186/s40880-015-0011-0
Export citations
EndNote
[ Html full-text / Citation export] (BioMed Central)
[Google Scholar]
[ More articles of the special series on Nasopharyngeal carcinoma ]
Cite this article
Jian-Wei Zhang, Tao Qin, Shao-Dong Hong, Jing Zhang, Wen-Feng Fang, Yuan-Yuan Zhao, Yun-Peng Yang, Cong Xue, Yan Huang, Hong-Yuan Zhao, Yu-Xiang Ma, Zhi-Huang Hu, Pei-Yu Huang and Li Zhang. Multiple oncogenic mutations related to targeted therapy in nasopharyngeal carcinoma. Chin J Cancer. 2015, 34:10. doi:10.1186/s40880-015-0011-0
Export citations
EndNote
SHARE THIS ARTICLE
Comments:
